Acquired resistance to cancer immunotherapy

Arianna Draghi; Christopher Aled Chamberlain; Andrew Furness; Marco Donia

doi:10.1007/s00281-018-0692-y

Acquired resistance to cancer immunotherapy

Arianna Draghi, Christopher Aled Chamberlain, Andrew Furness, Marco Donia

Department of Clinical Medicine

13 Citations (Scopus)

Abstract

In recent times, advances in cancer immunotherapy have yielded impressive, durable clinical responses in patients with varied subtypes of cancer. However, a significant proportion of patients who initially demonstrate encouraging tumor regression develop resistance and progress over time. The identification of novel therapeutic approaches to overcome resistance may result in significantly improved clinical outcomes and remains an area of high scientific priority. This review aims to summarize the current knowledge regarding the role of both tumor-intrinsic and tumor-extrinsic factors in the development of resistance to cancer immunotherapy and to discuss current and possible future therapeutic strategies targeting these mechanisms.

Original language	English
Journal	Seminars in Immunopathology
Volume	41
Pages (from-to)	31-40
ISSN	1863-2297
DOIs	https://doi.org/10.1007/s00281-018-0692-y
Publication status	Published - 11 Jan 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00281-018-0692-y

Cite this

@article{f3e3489f1810450aaf2f783b24d84ed6,

title = "Acquired resistance to cancer immunotherapy",

abstract = "In recent times, advances in cancer immunotherapy have yielded impressive, durable clinical responses in patients with varied subtypes of cancer. However, a significant proportion of patients who initially demonstrate encouraging tumor regression develop resistance and progress over time. The identification of novel therapeutic approaches to overcome resistance may result in significantly improved clinical outcomes and remains an area of high scientific priority. This review aims to summarize the current knowledge regarding the role of both tumor-intrinsic and tumor-extrinsic factors in the development of resistance to cancer immunotherapy and to discuss current and possible future therapeutic strategies targeting these mechanisms.",

author = "Arianna Draghi and Chamberlain, {Christopher Aled} and Andrew Furness and Marco Donia",

year = "2019",

month = jan,

day = "11",

doi = "10.1007/s00281-018-0692-y",

language = "English",

volume = "41",

pages = "31--40",

journal = "Seminars in Immunopathology",

issn = "1863-2297",

publisher = "Springer",

}

TY - JOUR

T1 - Acquired resistance to cancer immunotherapy

AU - Draghi, Arianna

AU - Chamberlain, Christopher Aled

AU - Furness, Andrew

AU - Donia, Marco

PY - 2019/1/11

Y1 - 2019/1/11

N2 - In recent times, advances in cancer immunotherapy have yielded impressive, durable clinical responses in patients with varied subtypes of cancer. However, a significant proportion of patients who initially demonstrate encouraging tumor regression develop resistance and progress over time. The identification of novel therapeutic approaches to overcome resistance may result in significantly improved clinical outcomes and remains an area of high scientific priority. This review aims to summarize the current knowledge regarding the role of both tumor-intrinsic and tumor-extrinsic factors in the development of resistance to cancer immunotherapy and to discuss current and possible future therapeutic strategies targeting these mechanisms.

AB - In recent times, advances in cancer immunotherapy have yielded impressive, durable clinical responses in patients with varied subtypes of cancer. However, a significant proportion of patients who initially demonstrate encouraging tumor regression develop resistance and progress over time. The identification of novel therapeutic approaches to overcome resistance may result in significantly improved clinical outcomes and remains an area of high scientific priority. This review aims to summarize the current knowledge regarding the role of both tumor-intrinsic and tumor-extrinsic factors in the development of resistance to cancer immunotherapy and to discuss current and possible future therapeutic strategies targeting these mechanisms.

U2 - 10.1007/s00281-018-0692-y

DO - 10.1007/s00281-018-0692-y

M3 - Review

C2 - 29968044

SN - 1863-2297

VL - 41

SP - 31

EP - 40

JO - Seminars in Immunopathology

JF - Seminars in Immunopathology

ER -

Acquired resistance to cancer immunotherapy

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this